Successful Rapid Desensitization to Ceftazidime/Avibactam in a Patient With Cystic Fibrosis and Multidrug-Resistant

Zuoren Zhou, Jinqi Zhu, Ge Wu, Xi Kang, Qing Wang, Jie Liu, Yan Jiang

Abstract read

In one paragraph

Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zuoren ZhouDepartment of Respiratory and Critical Care Medicine The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China Changsha Hunan China.ORCID https://orcid.org/0009-0009-7466-9309

Jinqi ZhuDepartment of Respiratory and Critical Care Medicine The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China Changsha Hunan China.

Ge WuDepartment of Pharmacy The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China Changsha Hunan China.

Xi KangDepartment of Respiratory and Critical Care Medicine The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China Changsha Hunan China.

Qing WangDepartment of Respiratory and Critical Care Medicine The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China Changsha Hunan China.

Jie LiuDepartment of Respiratory and Critical Care Medicine The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China Changsha Hunan China.

Yan JiangDepartment of Respiratory and Critical Care Medicine The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China Changsha Hunan China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ceftazidime/avibactam (CAZ-AVI) is an important therapeutic option for multidrug-resistant (MDR)

Indexed as

ceftazidime/avibactamcystic fibrosisdrug hypersensitivitymultidrug‐resistant Pseudomonas aeruginosarapid desensitization

Identifiers

PMID42553596

DOI10.1002/ccr3.73208

PMCPMC13435372

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.